Crystal Structure of the Papain-like Protease of MERS Coronavirus Reveals Unusual, Potentially Druggable Active-site Features

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2014 Jul 4

PMID 24992731

Citations 60

Authors

Jian Lei

Jeroen R Mesters

Christian Drosten

Stefan Anemuller

Qingjun Ma

Rolf Hilgenfeld

Affiliations

Soon will be listed here.

Abstract

The Middle-East Respiratory Syndrome coronavirus (MERS-CoV) causes severe acute pneumonia and renal failure. The MERS-CoV papain-like protease (PL(pro)) is a potential target for the development of antiviral drugs. To facilitate these efforts, we determined the three-dimensional structure of the enzyme by X-ray crystallography. The molecule consists of a ubiquitin-like domain and a catalytic core domain. The catalytic domain displays an extended right-hand fold with a zinc ribbon and embraces a solvent-exposed substrate-binding region. The overall structure of the MERS-CoV PL(pro) is similar to that of the corresponding SARS-CoV enzyme, but the architecture of the oxyanion hole and of the S3 as well as the S5 specificity sites differ from the latter. These differences are the likely reason for reduced in vitro peptide hydrolysis and deubiquitinating activities of the MERS-CoV PL(pro), compared to the homologous enzyme from the SARS coronavirus. Introduction of a side-chain capable of oxyanion stabilization through the Leu106Trp mutation greatly enhances the in vitro catalytic activity of the MERS-CoV PL(pro). The unique features observed in the crystal structure of the MERS-CoV PL(pro) should allow the design of antivirals that would not interfere with host ubiquitin-specific proteases.

Citing Articles

Frustration In Physiology And Molecular Medicine.

Parra R, Komives E, Wolynes P, Ferreiro D ArXiv. 2025; .

PMID: 39975445 PMC: 11838788.

Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.

Wu X, Go M, Nguyen J, Kuchel N, Lu B, Zeglinski K Nat Commun. 2024; 15(1):6219.

PMID: 39043718 PMC: 11266423. DOI: 10.1038/s41467-024-50566-9.

Local energetic frustration conservation in protein families and superfamilies.

Freiberger M, Ruiz-Serra V, Pontes C, Romero-Durana M, Galaz-Davison P, Ramirez-Sarmiento C Nat Commun. 2023; 14(1):8379.

PMID: 38104123 PMC: 10725452. DOI: 10.1038/s41467-023-43801-2.

Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins.

Ibeh R, Ikechukwu G, Ukweni C, Omekara I, Ezirim A, Ujowundu F Inform Med Unlocked. 2023; 38:101230.

PMID: 36974159 PMC: 10030444. DOI: 10.1016/j.imu.2023.101230.

Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies.

Ali Dahhas M, Alkahtani H, Malik A, Almehizia A, Bakheit A, Akber Ansar S Saudi Pharm J. 2022; 31(2):228-244.

PMID: 36540698 PMC: 9756750. DOI: 10.1016/j.jsps.2022.12.007.

References

Renatus M, Parrado S, DArcy A, Eidhoff U, Gerhartz B, Hassiepen U . Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure. 2006; 14(8):1293-302. PMC: 7126176. DOI: 10.1016/j.str.2006.06.012. View

Verschueren K, Pumpor K, Anemuller S, Chen S, Mesters J, Hilgenfeld R . A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem Biol. 2008; 15(6):597-606. PMC: 7110992. DOI: 10.1016/j.chembiol.2008.04.011. View

Chen V, Arendall 3rd W, Headd J, Keedy D, Immormino R, Kapral G . MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):12-21. PMC: 2803126. DOI: 10.1107/S0907444909042073. View

Baez-Santos Y, Barraza S, Wilson M, Agius M, Mielech A, Davis N . X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem. 2014; 57(6):2393-412. PMC: 3983375. DOI: 10.1021/jm401712t. View

Hartmann-Petersen R, Gordon C . Integral UBL domain proteins: a family of proteasome interacting proteins. Semin Cell Dev Biol. 2004; 15(2):247-59. DOI: 10.1016/j.semcdb.2003.12.006. View

Clementz M, Chen Z, Banach B, Wang Y, Sun L, Ratia K . Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol. 2010; 84(9):4619-29. PMC: 2863753. DOI: 10.1128/JVI.02406-09. View

Lindner H, Lytvyn V, Qi H, Lachance P, Ziomek E, Menard R . Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys. 2007; 466(1):8-14. PMC: 7094341. DOI: 10.1016/j.abb.2007.07.006. View

Anand K, Ziebuhr J, Wadhwani P, Mesters J, Hilgenfeld R . Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003; 300(5626):1763-7. DOI: 10.1126/science.1085658. View

Perlman S . The Middle East respiratory syndrome--how worried should we be?. mBio. 2013; 4(4). PMC: 3747588. DOI: 10.1128/mBio.00531-13. View

10.

Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y . Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol. 2013; 95(Pt 3):614-626. DOI: 10.1099/vir.0.059014-0. View

11.

Lindner H, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Menard R . The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol. 2005; 79(24):15199-208. PMC: 1316033. DOI: 10.1128/JVI.79.24.15199-15208.2005. View

12.

Reusken C, Haagmans B, Muller M, Gutierrez C, Godeke G, Meyer B . Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013; 13(10):859-66. PMC: 7106530. DOI: 10.1016/S1473-3099(13)70164-6. View

13.

Hu M, Li P, Li M, Li W, Yao T, Wu J . Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2003; 111(7):1041-54. DOI: 10.1016/s0092-8674(02)01199-6. View

14.

Devaraj S, Wang N, Chen Z, Chen Z, Tseng M, Barretto N . Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007; 282(44):32208-21. PMC: 2756044. DOI: 10.1074/jbc.M704870200. View

15.

Holm L, Rosenstrom P . Dali server: conservation mapping in 3D. Nucleic Acids Res. 2010; 38(Web Server issue):W545-9. PMC: 2896194. DOI: 10.1093/nar/gkq366. View

16.

Woo P, Huang Y, Lau S, Yuen K . Coronavirus genomics and bioinformatics analysis. Viruses. 2011; 2(8):1804-1820. PMC: 3185738. DOI: 10.3390/v2081803. View

17.

de Groot R, Baker S, Baric R, Brown C, Drosten C, Enjuanes L . Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790-2. PMC: 3700179. DOI: 10.1128/JVI.01244-13. View

18.

Riddles P, Blakeley R, ZERNER B . Reassessment of Ellman's reagent. Methods Enzymol. 1983; 91:49-60. DOI: 10.1016/s0076-6879(83)91010-8. View

19.

Ratia K, Kilianski A, Baez-Santos Y, Baker S, Mesecar A . Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 2014; 10(5):e1004113. PMC: 4031219. DOI: 10.1371/journal.ppat.1004113. View

20.

Zhu L, George S, Schmidt M, Al-Gharabli S, Rademann J, Hilgenfeld R . Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 2011; 92(2):204-12. PMC: 7114241. DOI: 10.1016/j.antiviral.2011.08.001. View